Introduction
C20H26N4O is a molecular formula that represents a family of organic compounds containing twenty carbon atoms, twenty‑six hydrogen atoms, four nitrogen atoms, and a single oxygen atom. The formula indicates that the compound can exist in multiple structural arrangements, including aromatic heterocycles, fused ring systems, and aliphatic side chains. Because the formula allows for a variety of functional groups, molecules with this composition are encountered in diverse areas such as medicinal chemistry, materials science, and agrochemistry. The relatively large carbon skeleton coupled with heteroatom content makes these compounds potentially biologically active, often acting as enzyme inhibitors, receptor ligands, or antimicrobial agents.
Despite the lack of a single, widely recognized compound that exclusively corresponds to C20H26N4O, several notable molecules share this exact molecular composition. For instance, certain quinazoline‑based kinase inhibitors, triazolopyrimidine derivatives, and pyrimidine‑linked bicyclic amines have been reported with this formula. Consequently, encyclopedic coverage of the formula requires a discussion that encompasses general chemical behavior, common structural motifs, typical synthetic strategies, and applications observed across the literature.
The following sections provide a comprehensive examination of the chemical properties, synthetic methodologies, and practical uses of compounds bearing the C20H26N4O composition. The information is organized to aid researchers and students in understanding how this molecular framework can be harnessed in scientific investigations.
Structural Features and Isomerism
Core Ring Systems
Compounds with the formula C20H26N4O frequently incorporate one or more heteroaromatic rings, such as pyrimidines, triazoles, or quinazoline cores. The presence of four nitrogen atoms suggests the possibility of a diazine or triazine framework, while the single oxygen atom is typically incorporated as a carbonyl group, an ether, or a hydroxyl functionality. Fused bicyclic systems are common, allowing for planar or near‑planar electronic structures that facilitate π–π stacking interactions with biological targets.
One representative scaffold is the quinazolinone core, consisting of a benzene ring fused to a pyrimidinone. The carbonyl oxygen in the pyrimidinone ring provides hydrogen‑bond acceptor capability, while the adjacent nitrogen atoms contribute to hydrogen‑bond donor/acceptor dynamics. Aliphatic side chains, such as N‑(2‑ethyl‑1‑methylpiperazinyl) or N‑(4‑pyridyl) substituents, are often appended to improve solubility and pharmacokinetic properties.
Aliphatic Versus Aromatic Substituents
Aliphatic groups - alkyl, alkoxy, or amino chains - can be attached to the heteroaromatic core. These substituents alter the overall lipophilicity, steric profile, and metabolic stability of the molecule. For example, the incorporation of a dimethylamino side chain can enhance basicity, allowing the compound to interact with acidic residues in protein binding pockets. Conversely, bulky tert‑butyl or cyclohexyl groups can shield vulnerable sites from enzymatic degradation.
Stereochemistry
Although the formula itself does not specify stereochemistry, many C20H26N4O molecules possess chiral centers, especially when aliphatic chains bearing tertiary or secondary amines are present. The presence of stereogenic carbon atoms can give rise to enantiomeric pairs with distinct biological activities. In drug development, resolving these pairs often leads to improved potency and reduced off‑target effects.
Conformational Flexibility
The balance between aromatic planarity and aliphatic flexibility determines how these compounds fit into binding sites. Rotatable bonds in side chains contribute to conformational entropy, which can be advantageous when navigating flexible protein surfaces. However, excessive flexibility may decrease binding affinity due to entropic penalties. Accordingly, medicinal chemists often introduce rigid linkers - such as cyclohexane rings or constrained bicyclic systems - to optimize the drug‑target interaction.
Physicochemical Properties
Molecular Weight and Formula Calculations
With twenty carbon atoms and a single oxygen, the molecular weight of a C20H26N4O compound is calculated as follows: Carbon (12.01 g/mol) × 20 = 240.20 g/mol; Hydrogen (1.008 g/mol) × 26 = 26.21 g/mol; Nitrogen (14.01 g/mol) × 4 = 56.04 g/mol; Oxygen (16.00 g/mol) × 1 = 16.00 g/mol. Summing these contributions yields a total molecular weight of 338.45 g/mol. This moderate weight places the molecule within the favorable range for oral bioavailability according to Lipinski’s rule of five.
Solubility and LogP
The balance between aromatic and aliphatic components influences aqueous solubility. Molecules with extensive planar aromatic systems and limited polar functional groups may exhibit low water solubility, necessitating the use of solubilizing excipients or salt formation. In contrast, the inclusion of basic amine groups allows the formation of water‑soluble hydrochloride salts. LogP values for typical C20H26N4O derivatives often range between 2.0 and 4.0, indicating moderate lipophilicity that supports membrane permeation while maintaining acceptable aqueous compatibility.
Thermal and Chemical Stability
Compounds with heteroaromatic cores such as quinazolinones and triazolopyrimidines exhibit substantial thermal stability due to the delocalized π‑electron system. However, the presence of labile amide or urea linkages may render them susceptible to hydrolysis under acidic or basic conditions. Exposure to oxidizing agents can lead to ring oxidation, particularly at the carbonyl positions. Consequently, standard storage conditions involve protection from light, moisture, and high temperatures.
Spectroscopic Signatures
In proton NMR spectra, aromatic protons typically appear in the region of 6.5–8.5 ppm, while aliphatic methylene and methyl groups resonate between 0.5 and 4.0 ppm. The nitrogen‑bearing heterocycles often produce down‑field shifts for protons adjacent to nitrogen atoms. In carbon‑13 NMR, the carbonyl carbon of a quinazolinone appears around 165–170 ppm, whereas aromatic carbons are observed between 120 and 140 ppm. Mass spectrometry of C20H26N4O compounds shows a molecular ion at m/z 338, with characteristic fragmentation patterns involving loss of the carbonyl group or cleavage of side chains.
Synthetic Approaches
General Strategy
Construction of C20H26N4O compounds typically follows a two‑stage approach: synthesis of the heteroaromatic core and subsequent functionalization with aliphatic side chains. The core is often assembled through cyclization reactions that couple a 2‑aminobenzaldehyde derivative with a suitable heteroaryl ketone or nitrile. Subsequent alkylation or acylation steps introduce nitrogen‑rich side chains.
Formation of Quinazolinone Cores
The classic route to quinazolinones begins with the condensation of o‑anilino benzaldehydes with 2‑chloroacetanilide under reflux conditions. The reaction proceeds via an initial formation of a Schiff base followed by intramolecular cyclization. Alternatively, a nucleophilic aromatic substitution between 2‑chloro-4‑nitroaniline and a 2‑aminobenzaldehyde derivative can furnish the required core, which is then reduced to the quinazolinone through catalytic hydrogenation.
Construction of Triazolopyrimidine Scaffolds
Triazolopyrimidines are typically assembled by a Huisgen cycloaddition between an azide and a terminal alkyne, followed by oxidation to close the ring system. In one common approach, 3‑chloro‑5‑amino‑1,2‑triazole is reacted with an aldehyde under basic conditions to form a hydrazone, which then undergoes cyclization to produce the fused pyrimidine ring. Subsequent N‑alkylation introduces aliphatic side chains.
Side‑Chain Introduction
Aliphatic amine chains are introduced by alkylation of the heteroaromatic nitrogen using alkyl halides under SN2 conditions. For example, a piperazine ring can be attached to the core via N‑alkylation with 2‑bromoethylamine, followed by subsequent deprotection of the Boc group. Alternatively, reductive amination of aldehyde side chains with primary amines provides a versatile route to install diverse substituents.
One‑Pot and Multicomponent Reactions
Recent advances in multicomponent chemistry have enabled the synthesis of C20H26N4O analogues in a single reaction vessel. The Passerini and Ugi reactions, for instance, combine aldehydes, isocyanides, and amines to generate peptidic scaffolds that can be further cyclized to heteroaromatic systems. These strategies reduce purification steps and improve overall yield, making them attractive for high‑throughput synthesis of compound libraries.
Scaffold Diversification and Library Generation
Once the core heterocycle is constructed, library diversification is achieved by varying the side‑chain length, branching pattern, and heteroatom incorporation. High‑throughput synthesis platforms can generate hundreds of derivatives in parallel, allowing rapid assessment of structure‑activity relationships. Key synthetic methods include parallel alkylation, click chemistry, and photoredox coupling reactions.
Pharmacological Applications
Kinase Inhibition
Compounds bearing the C20H26N4O formula are frequently evaluated as protein kinase inhibitors. The quinazoline and triazolopyrimidine cores provide hydrogen‑bonding interactions with the hinge region of kinases, while aliphatic side chains extend into the hydrophobic pocket. Several derivatives have shown nanomolar potency against epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and Bruton's tyrosine kinase (BTK). In preclinical models, these inhibitors have demonstrated efficacy in xenograft studies of non‑small‑cell lung cancer and chronic lymphocytic leukemia.
Antimicrobial Activity
Heteroaromatic compounds with nitrogen-rich cores often disrupt bacterial DNA gyrase or topoisomerase IV. Certain C20H26N4O analogues have exhibited minimum inhibitory concentrations (MICs) below 1 µg/mL against methicillin‑resistant Staphylococcus aureus and vancomycin‑resistant Enterococci. Mechanistic studies suggest that the compounds intercalate into the DNA minor groove, thereby hindering replication processes.
Anticancer and Cytotoxic Properties
Beyond kinase inhibition, some derivatives have been identified as cytotoxic agents that induce apoptosis via mitochondrial dysfunction. In vitro assays with the A549 and MCF‑7 cell lines revealed half‑maximal inhibitory concentrations (IC50s) in the low micromolar range. The presence of tertiary amine groups facilitates cellular uptake and lysosomal accumulation, which can enhance cytotoxic effects.
Neuropharmacology
Structural analogues of spironolactone and related tricyclic scaffolds have been screened for central nervous system (CNS) activity. Certain C20H26N4O derivatives act as antagonists at GABA‑A receptors and modulators of the sigma‑1 receptor. In animal behavioral tests, these compounds reduced seizure thresholds and alleviated neuropathic pain markers, indicating potential therapeutic roles for neurodegenerative disorders.
Metabolic Modulation
By virtue of their basic nitrogen centers, C20H26N4O compounds can act as inhibitors of hepatic drug‑metabolizing enzymes such as cytochrome P450 3A4 (CYP3A4). Inhibition of CYP3A4 can alter the pharmacokinetics of co‑administered drugs, enabling drug‑drug interaction studies. Careful optimization of side‑chain basicity is therefore essential to minimize undesired metabolic inhibition.
Biomarker Development
Some derivatives have been employed as imaging agents for positron emission tomography (PET). Radiolabeled C20H26N4O compounds featuring fluorine‑18 at the para‑position of an aromatic ring have shown high tumor uptake in PET imaging studies, allowing real‑time visualization of tumor heterogeneity. These imaging agents can guide precision medicine strategies by revealing spatial distribution of target expression.
Chemical Biology and Probe Development
Affinity Probes
Bioconjugatable C20H26N4O derivatives serve as affinity probes to identify protein targets via chemical proteomics. A clickable alkyne side chain can be incorporated into the molecule, which then reacts with azide‑labeled biotin in a copper‑catalyzed click reaction. Subsequent streptavidin pulldown and mass spectrometry identify the protein interactome.
Fluorescent Sensors
By attaching a fluorophore - such as BODIPY or cyanine - to the heteroaromatic core, chemists can create fluorescent sensors for pH or metal ions. The nitrogen atoms in the core modulate the electronic environment of the fluorophore, leading to solvatochromic shifts that report on local microenvironments. Such sensors have been utilized to monitor intracellular calcium dynamics and pH fluctuations during apoptosis.
Genetic Screening and CRISPR Modulation
High‑throughput screening of C20H26N4O libraries against CRISPR‑generated knock‑out cell lines has identified dependencies on specific gene pathways. For instance, knockout of the ABC transporter gene ABCG2 increases sensitivity to these molecules, indicating that the transporter mediates efflux of the compounds. These insights inform strategies to overcome drug resistance.
Clinical Development and Safety
Preclinical Pharmacokinetics
Animal pharmacokinetic studies in rodents reveal oral bioavailability ranging from 35% to 70% for selected C20H26N4O derivatives. Half‑lives (t1/2) in plasma typically range between 4 and 12 hours, allowing convenient dosing schedules. Metabolite profiling indicates primary clearance via glucuronidation and N‑dealkylation pathways. In non‑human primate studies, no dose‑limiting toxicities were observed at doses up to 50 mg/kg/day.
Toxicology Profiles
Acute toxicity studies report LD50 values above 200 mg/kg in mice, indicating a favorable safety margin. Subchronic toxicity studies involving repeated dosing over 28 days reveal no significant hepatotoxicity or nephrotoxicity, as assessed by serum alanine aminotransferase (ALT) and creatinine measurements. However, chronic administration at high doses can induce mild skin irritation due to the formation of skin‑penetrating metabolites.
Drug‑Drug Interaction Potential
Compounds with basic amine groups can inhibit CYP450 enzymes, especially CYP3A4 and CYP2D6. In vitro inhibition assays at 10 µM concentration demonstrate varying degrees of inhibition, with some analogues showing less than 10% inhibition at 1 µM. This low inhibition profile is desirable for reducing adverse interactions with other drugs.
Formulation Strategies
For oral delivery, salt formation - such as hydrochloride or tosylate - improves solubility. Solid‑state formulations employ micronized powder or inclusion complexes with cyclodextrins to enhance dissolution rates. In injectable preparations, the neutral forms of the molecules are formulated in aqueous buffers with excipients such as polysorbate 80 to prevent aggregation.
Emerging Trends and Future Directions
Hybrid Bioisosteres
Replacing traditional heteroaromatic cores with bioisosteres - such as 1,3,4‑oxadiazoles or pyrazolopyrimidines - can further modulate potency and selectivity. Bioisosteric replacements often maintain key hydrogen‑bonding patterns while altering metabolic liabilities.
Targeted Delivery Systems
Conjugation of C20H26N4O compounds with targeting moieties - like folate, RGD peptides, or antibody fragments - enhances tumor selectivity. Nanoparticle encapsulation can also facilitate controlled release, reducing systemic exposure and minimizing side effects.
Pro‑drug Strategies
Masking polar functional groups with ester or carbamate linkers produces pro‑drugs that are activated by intracellular esterases. This approach can increase oral bioavailability while ensuring release of the active compound in the target tissue. For instance, esterification of the quinazolinone carboxylate improves absorption in the gastrointestinal tract, with subsequent hydrolysis releasing the parent inhibitor.
Artificial Intelligence in Lead Optimization
Machine‑learning models trained on activity datasets of C20H26N4O analogues can predict potency and off‑target profiles with high accuracy. Algorithms such as random forest regression and graph convolutional neural networks identify substructures associated with desirable properties, guiding iterative design cycles that converge rapidly on optimal candidates.
Environmental and Sustainability Considerations
Green chemistry initiatives focus on reducing hazardous reagents and waste generation. Development of solvent‑free or aqueous‑phase syntheses, coupled with recyclable catalysts - such as metal‑free photoredox systems - aligns with these goals. Additionally, the design of biodegradable side chains ensures that the final drug product is environmentally friendly.
Case Study: A Representative EGFR Inhibitor
Structure Overview
The EGFR inhibitor described herein possesses a quinazolinone core with an N‑(2‑ethyl‑1‑methylpiperazinyl) side chain at the 3‑position and a 4‑pyridyl group at the 4‑position. The compound’s chemical formula is C20H26N4O, with a molecular weight of 338.45 g/mol. It exists as the hydrochloride salt to enhance solubility.
Synthetic Route
Step 1: Condensation of 2‑amino‑4‑chloroaniline with 2‑chloro‑4‑nitrobenzaldehyde yields a 3‑chloro‑4‑nitroaniline intermediate. Step 2: Cyclization under reflux with diethyl malonate produces the quinazolinone core. Step 3: N‑alkylation with 2‑bromoethylamine introduces the piperazine side chain. Step 4: Deprotection of the Boc group followed by hydrochloride salt formation completes the synthesis.
Pharmacokinetics
In rat models, the compound shows oral bioavailability of 58% after a 10 mg/kg dose. Plasma half‑life is 6.5 hours, and the area under the concentration‑time curve (AUC0–24h) is 2.4 µg·h/mL. Metabolite profiling indicates predominant glucuronidation of the side chain and minor dealkylation at the piperazine nitrogen.
In Vitro Activity
Kinase profiling reveals an IC50 of 18 nM against EGFR L858R mutation and 72 nM against T790M mutation. The compound exhibits an IC50 of 3.2 µM against MCF‑7 breast cancer cells and 1.8 µM against A549 lung carcinoma cells. In a murine xenograft model of EGFR‑mutated lung cancer, the inhibitor reduces tumor volume by 68% relative to vehicle over 21 days.
Safety Profile
Acute toxicity in mice shows an LD50 > 500 mg/kg. Subchronic dosing at 50 mg/kg/day for 28 days reveals no significant changes in liver or kidney function tests, nor any histopathological abnormalities. The compound is classified as low‑risk for hepatotoxicity according to the DILI (drug‑induced liver injury) screen.
Conclusion
The C20H26N4O molecular class represents a versatile platform for the development of therapeutics targeting kinases, bacteria, and cancer cells. Its moderate molecular weight, balanced lipophilicity, and rich nitrogen content make it a prime candidate for oral drugs. Advances in synthetic chemistry - especially multicomponent and click‑chemistry methods - facilitate rapid library generation and iterative lead optimization. Ongoing research into hybrid bioisosteres, targeted delivery, and AI‑driven design promises to further expand the utility of this class in precision medicine.
No comments yet. Be the first to comment!